Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Lancet

• Publication date

  2012-06-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(12)60239-6PMID 22560607
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Maintenance treatment with antipsychotic drugs for schizophrenia.

  2012cited by this paper
• Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials.

  2011cited by this paper
• Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: Results from an aborted randomised trial

  2011cited by this paper
• A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment.

  2011cited by this paper
• A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

  2011cited by this paper
• Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

  2010cited by this paper
• CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

  2010cited by this paper
• A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis.

  2010cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions

  2010cited by this paper
• International consensus study of antipsychotic dosing.

  2010cited by this paper
• Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial

  2010cited by this paper
• 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

  2009cited by this paper
• Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

  2009cited by this paper
• The natural history

  2009cited by this paper
• Atypical antipsychotic drugs and the risk of sudden cardiac death.

  2009cited by this paper
• Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry.

  2008cited by this paper
• Paliperidone Extended-Release Tablets for Prevention of Symptom Recurrence in Patients With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study

  2007cited by this paper
• Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.

  2007cited by this paper
• Prophylactic effect of neuroleptics in symptom-free schizophrenics

  2004cited by this paper
• Schizophrenia. Full National Clinical Guideline on Core Interventions in Primary and Secondary Care National Collaborating Centre for Mental Health

  2004cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

  2003cited by this paper
• Optimizing pharmacologic treatment of psychotic disorders

  2003cited by this paper
• Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

  2003cited by this paper
• A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

  2003cited by this paper
• The Natural History

  2002cited by this paper
• A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

  2002cited by this paper
• Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia

  2000cited by this paper
• Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis

  2000cited by this paper
• Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.

  1999cited by this paper
• Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

  1999cited by this paper
• Confidence intervals for the number needed to treat

  1998cited by this paper
• Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.

  1997cited by this paper
• Neuroleptic withdrawal in schizophrenic patients. A review of the literature.

  1995cited by this paper
• Depot antipsychotic drugs. Place in therapy.

  1994cited by this paper
• Intermittent versus maintenance neuroleptic long-term treatment in Schizophrenia—2-year results of a German multicenter study

  1993cited by this paper
• Neuroleptic discontinuation in the very stable schizophrenic patient: Relapse rates and serum neuroleptic levels

  1992cited by this paper
• Continuous versus targeted medication in schizophrenic outpatients: outcome results.

  1990cited by this paper
• The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics.

  1989cited by this paper
• II. A Randomised Controlled Trial of Prophylactic Neuroleptic Treatment

  1986cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures.

  1984cited by this paper
• Research diagnoses for tardive dyskinesia.

  1982cited by this paper
• Schizophrenics Fully Remitted on Neuroleptics for 3–5 years—To Stop or Continue Drugs?

  1981cited by this paper
• Lack of tolerance to long‐term neuroleptic treatment in dopamine tuberoinfundibular system

  1981cited by this paper
• Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.

  1980cited by this paper
• Overview: maintenance therapy in psychiatry: I. Schizophrenia.

  1975cited by this paper
• Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates.

  1974cited by this paper
• Pimozide (orap, R 6238) in residual schizophrenia. A clinical evaluation with long-term double-blind follow-up.

  1973cited by this paper
• Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates.

  1973cited by this paper
• Pimozide (orap, R 6238) in residual schizophrenia. A clinical evaluation with long-term double-blind follow-up.

  1973cited by this paper
• Trial of Maintenance Therapy in Schizophrenia*

  1971cited by this paper
• Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients.

  1966cited by this paper
• DISCONTINUATION OR REDUCTION OF CHEMOTHERAPY IN CHRONIC SCHIZOPHRENICS.

  1964cited by this paper

• Lurasidone continuation in real-world clinical cases in Japan: retrospective study of factors associated with six-month persistence.

  2026cites this paper
• Delivering culturally adapted family interventions for people with schizophrenia in Indonesia: A feasibility randomised controlled trial and nested process evaluation

  2026cites this paper
• Exploring Predictors of Self-Management Abilities for Early Relapse Signs in Individuals With Schizophrenia and Their Caregivers.

  2026cites this paper
• Outcome of first episode and relapsing patients with schizophrenia presenting to a tertiary care hospital in Sri Lanka: A prospective one year follow up study.

  2026cites this paper
• Benefits and risks of antipsychotic discontinuation in people with first and multi-episode psychotic disorders or with schizophrenia: why, when, how and in whom?

  2025cites this paper
• Psychological Therapies for Schizophrenia and Other Primary Psychotic Disorders: Toward Precision, Personalization, and Real-World Impact.

  2025cites this paper
• The association between relapse and the outcome of schizophrenia and recurrent psychotic disorders

  2025cites this paper
• Clinical Outcomes in Patients with Schizophrenia Treated with Long-Acting Injectable vs. Oral Antipsychotics: A Naturalistic Study

  2025cites this paper
• Treatment adherence in first-episode psychosis: A one-year follow-up study comparing self-reported adherence, pharmacy refill data, and therapeutic drug monitoring.

  2025cites this paper
• Use of long-acting injectable antipsychotics in an acute inpatient psychiatric unit and 90-day re-hospitalization rates: results of an observational prospective study

  2025cites this paper
• HMG‐CoA reductase inhibitors (statins) versus placebo for people with schizophrenia

  2025cites this paper
• Relating positively and openly with voices through dialogue: A talking with voices implementation guide for mental health practitioners.

  2025cites this paper
• Trajectory analysis of BMI increase induced by second-generation antipsychotics in first-episode schizophrenia: a secondary analysis based on CNFEST****

  2025cites this paper
• Cannabinoids and Extracellular Vesicles as Potential Biomarkers and Therapeutic Targets in Neuropsychiatric Disorders: A Hypothesis-Driven Review

  2025cites this paper
• Empowering clinicians and patients in antipsychotic dose reduction for schizophrenia: the role of online tools

  2025cites this paper
• The place of risperidone in situ microparticles (ISM®) among long-acting injectable antipsychotics in schizophrenia treatment

  2025cites this paper
• Management of schizophrenia patients in acute setting – a multinational survey of prescription patterns in five European countries

  2025cites this paper
• The Effects of Antipsychotic Dose Reduction on Movement Disorders and Cardiometabolic Indices in Patients Remitted from a First Episode of Psychosis.

  2025cites this paper
• Effect of social resources on readmission prevention and the influence of informal coercion in acute schizophrenia: a retrospective quasi-experimental cohort study.

  2025cites this paper
• Preparation of paliperidone palmitate nanosuspensions and investigation of factors influencing their stability

  2025cites this paper
• A Review of Pharmacokinetic and Pharmacodynamic Properties of Quetiapine IR and XR: Insights and Clinical Practice Implications

  2025cites this paper
• When Shared Decision-Making Breaks Down: Solving Moral Dilemmas in Antipsychotic Deprescribing

  2025cites this paper
• Investigation of risperidone oral solution administration practices and risk of beverage-related drug interactions in Japanese patients

  2025cites this paper
• The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment

  2025cites this paper
• Treatment discontinuation of remotely delivered cognitive remediation for schizophrenia: a systematic review and meta-analysis

  2025cites this paper
• A Scoping Review of Methods, Guidelines, and Protocols Used for Dose Reduction or Discontinuation of Antipsychotic Medication in People Affected by Psychotic Disorders.

  2025cites this paper
• Unveiling the prognosis of adult Catatonia: A systematic review.

  2025cites this paper
• MindMate: An Application for Symptom Monitoring and Clinical Support in Schizophrenia

  2025cites this paper
• Family and informal carers' views and experiences of antipsychotic reduction and discontinuation within a medication reduction research trial.

  2025cites this paper
• Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia

  2025cites this paper
• Helping people to discontinue antipsychotics: if, when and how

  2025influential citation
• Mannich Bases: Promising Scaffolds for the Treatment of Infectious Diseases.

  2025cites this paper
• Halved Dose of Antipsychotics Versus High-Dose Antipsychotic Therapy for Relapse in Patients with Schizophrenia Receiving High-Dose Antipsychotic Therapy: A Randomized Single-Blind Trial

  2025cites this paper
• Antipsychotic treatment in schizophrenia: balancing relapse prevention and functional recovery

  2025cites this paper
• Hyperlearning Hypothesis: Network disruption and maladaptive learning in schizophrenia.

  2025cites this paper
• Impact of Antipsychotic Therapy on Length of Stay and Excitement Symptoms in Patients with Schizophrenia

  2025cites this paper
• Repurposed antihypertensive drugs for negative symptoms in schizophrenia: A systematic review and meta‐analysis

  2025cites this paper
• Efficacy and safety of celecoxib in schizophrenia: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• The ILIA study: protocol for a randomized-controlled multicenter clinical trial on smartphone- and web-based relapse monitoring for patients with schizophrenia or schizoaffective disorder

  2025cites this paper
• Long-term outcomes of Aripiprazole long-acting injectable: a 10-year mirror image study of patient acceptability and treatment effectiveness

  2025cites this paper
• Medications for psychosis in people with schizophrenia: what happens if you take them and what happens if you don’t?

  2025cites this paper
• Self-reported attitudes and strategies of physicians towards medication reduction and discontinuation.

  2025cites this paper
• Relationship between medication use and non‐attendance (missed appointment) from primary care visits among people with type 2 diabetes: The Japan Diabetes Outcome Intervention Trial‐2 Large‐Scale Trial 006 (J‐DOIT2‐LT006)

  2025cites this paper
• The Impact of Medication Non-adherence on Adverse Outcomes: Evidence from Schizophrenia Patients via Survival Analysis

  2025cites this paper
• Pharmacogenomics-guided treatment versus conventional treatment in patients with Schizophrenia: Evaluation of medication adherence and switching rate

  2025cites this paper
• Unravelling the genetic and molecular basis of low-frequency rTMS induced changes in functional connectivity density in schizophrenia patients with auditory verbal hallucinations

  2025cites this paper
• Dopamine D2/3R availability after discontinuation of antipsychotic treatment: a [11C]raclopride PET study in remitted first-episode psychosis patients

  2025cites this paper
• Using Smartphone-Based Digital Phenotyping to Predict Relapse in Serious Mental Disorders Among Slum Residents in Dhaka, Bangladesh: Protocol for a Machine Learning Study

  2025cites this paper
• The knowledge and attitudes of psychiatrists toward antipsychotic long-acting injections in Turkiye

  2025cites this paper
• Impact of CYP1A, CYP2C19, CYP2D6, CYP3A4, CYP3A5, and NFIB genotypes on clozapine serum concentration in smokers and nonsmokers

  2025cites this paper
• Antipsychotic discontinuation in schizophrenia: rational or reckless?

  2025cites this paper
• Do antipsychotics work in people with schizophrenia? A review of outcomes and effect sizes

  2025cites this paper
• Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.

  2025cites this paper
• Differences in infant feeding methods at one month postpartum among women with psychiatric disorders and factors influencing exclusive breastfeeding

  2025cites this paper
• Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials

  2025cites this paper
• Effectiveness of antipsychotic medication in patients with schizophrenia in a real world retrospective observational study in Ethiopia

  2025cites this paper
• Distribution and correlates of long-acting injectable antipsychotic use among community mental health center patients.

  2025cites this paper
• Forty years of research trends in long-acting injectable antipsychotics: A bibliometric analysis

  2025cites this paper
• A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics.

  2025cites this paper
• Comparison of Efficacies of a Blonanserin Transdermal Patch and Blonanserin Oral Formulation for Psychiatric Symptoms in Patients With Schizophrenia Treated With Laxatives Using a Japanese Claims Database

  2025cites this paper
• Do antipsychotic medications work: An exploration using competency to stand trial as the functional outcome.

  2025cites this paper
• Continuous Dopamine D2 Receptor Blockade and Long-Term Outcome in First-Episode Schizophrenia.

  2025cites this paper
• Medication- and Non-Medication-Related Causes of Relapse in First-Episode Psychosis Patients Admitted to Sultan Qaboos University Hospital

  2025cites this paper
• Antipsychotika abseits der Dopamin-D2-Blockade – Xanomelin-Trospium als Hoffnungsträger?

  2025cites this paper
• Prediction of relapse in a French cohort of outpatients with schizophrenia (FACE-SZ): Prediction, not association.

  2025cites this paper
• Antipsychotic drug dosing and study discontinuation in schizophrenia: A systematic review and dose-response meta-analysis.

  2025cites this paper
• Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomized phase 2a study.

  2025cites this paper
• Kronik ruhsal bozukluk tanısı alan hastalarının toplum ruh sağlığı merkezine devam durumuna göre sosyal işlevsellik, iç görü ve ilaç uyumlarının karşılaştırılması

  2024cites this paper
• What is it all about? An explorative study of patients’ experiences with medication free treatment

  2024cites this paper
• Changes in the pharmacokinetics of lurasidone in a pregnant woman with schizophrenia

  2024cites this paper
• Effectiveness of salivary-gland and oral-mucosa massage in alleviating xerostomia in patients with schizophrenia

  2024cites this paper
• Concepts of Mental Disorders Among Psychiatrists, Psychologists, and Theologians

  2024cites this paper
• Guideline for pharmacological treatment of schizophrenia 2022

  2024cites this paper
• The development of paliperidone nanocrystals for the treatment of schizophrenia

  2024cites this paper
• Co-designing a low-intensity psychological therapy for fear of recurrence in psychosis using translational learning from fear of recurrence in oncology: protocol for intervention development for future testing in a feasibility study

  2024cites this paper
• Relapse Following Electroconvulsive Therapy for Schizophrenia: A Systematic Review and Meta-analysis

  2024cites this paper
• Cardiometabolic biomarkers and comorbid metabolic syndrome in schizophrenia: A cross-sectional study of long-term clozapine/olanzapine users.

  2024cites this paper
• Deconstructing the Language of Psychotherapy Documentation

  2024cites this paper
• Risk factors and strategies for relapse prevention among individuals living with serious mental illness in South Africa: Qualitative inquiry from patients’ and caregivers’ perspectives

  2024cites this paper
• Developing a validated methodology for identifying clozapine treatment periods in electronic health records

  2024cites this paper
• Cost-Utility Analysis of Antipsychotic Reduction and Discontinuation in Patients with Long-term Schizophrenia and Psychosis in English Mental Health Trusts: The RADAR Study.

  2024cites this paper
• Drug nanocrystals: Surface engineering and its applications in targeted delivery

  2024cites this paper
• Introducing S.C.O.P.E.™ (Schizophrenia Clinical Outcome Scenarios and Patient–Provider Engagement), an Interactive Digital Platform to Educate Healthcare Professionals on Schizophrenia Care

  2024cites this paper
• A randomised controlled trial of interventions to promote adoption of physical activity in adults with severe mental illness

  2024cites this paper
• Gradually tapering off antipsychotics: lessons for practice from case studies and neurobiological principles

  2024cites this paper
• Differential impact of intermittent versus continuous treatment with clozapine on fatty acid metabolism in the brain of an MK-801-induced mouse model of schizophrenia.

  2024cites this paper
• On the Road to Individualizing Pharmacotherapy for Adolescents and Adults with Schizophrenia – Results from an Expert Consensus Following the Delphi Method

  2024cites this paper
• Comparing the latent state–trait structure of the PANSS in cariprazine-medicated and placebo-controlled patients with acute schizophrenia

  2024cites this paper
• The effect of online group based acceptance and commitment therapy on psychotic symptoms and functioning levels of individuals with early psychosis.

  2024cites this paper
• Reducing Distress from Auditory Verbal Hallucinations: A Multicenter, Parallel, Single-Blind, Randomized Controlled Feasibility Trial of Relating Therapy

  2024cites this paper
• Utjecaj dugodjelujućih antipsihotika na hospitalizaciju oboljelih od shizofrenije u Republici Hrvatskoj

  2024influential citation
• Novel long-acting treatment for schizophrenia based on paliperidone dissolving and implantable microarray patches.

  2024cites this paper
• Using in silico methods to determine optimal tapering regimens for decanoate-based long-acting injectable psychosis drugs

  2024influential citation
• Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application.

  2024cites this paper
• Clinical experiences of guided tapering of antipsychotics for patients with schizophrenia– a case series

  2024cites this paper
• Group arts therapies for patients with schizophrenia: a protocol of systematic review and meta-analysis

  2024cites this paper
• Associations of Systemic Inflammation and Senescent Cell Biomarkers with Clinical Outcomes in Older Adults with Schizophrenia

  2024cites this paper
• The Swedish version of the Motivation and Pleasure Scale self-report (MAP-SR): psychometric properties in patients with schizophrenia or depression

  2024cites this paper
• Functioning and Cognition in Patients with Schizophrenia After Initiating Treatment with Aripiprazole Lauroxil: Secondary Outcomes and Post Hoc Analysis.

  2024cites this paper
• A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort.

  2024cites this paper